SYSTEMIC HEMOSTATIC AND PROTHROMBOTIC EFFECTS OF FIBRIN-MONOMER IN EXPERIMENT WITH DOSED LIVER THERAPY

Author: Momot A.P.¹, Vdovin V.M.², Shakhmatov I.I.³, Tolstokorov I.G.⁴, Orekhov D.A.⁵, Shevchenko V.O.⁶, Lycheva N.A.⁷, Kudinov A.V.⁸, Belozerskaya G.G.⁹, Kiselev V.I.¹⁰

Author Affiliations

Abstract

Objective of the study is to experimentally evaluate system hemostatic and prothrombotic effects of intravenous fibrin monomer (FM). Materials and methods. Eighty two Chinchilla rabbits weighing 3–4 kg were used in the study. In addition to the placebo, animals were administered an aqueous solution of fibrin monomer (FM) intravenously at doses of 0.1, 0.25, 0.5, 1.0, 2.5 and 5.0 mg/kg. After 1 hour, a standard liver injury was performed and the blood loss (% of the circulating blood volume) resulting from parenchymal hemorrhage was estimated. Hemostatic system examination included platelet number in venous blood and fibrinogen and D-dimer levels in blood plasma. Results and discussion. Blood loss after dosed injury with placebo was 10.0 [4.0; 15.7] % blood volume (median [25th percentile; 75th percentile]). FM preparation doses of 0.25, 2.5 and 5.0 mg/kg resulted in a decrease of blood loss by 6.3 (p < 0.001), 7.8 (p < 0.001) and 2.7 times (p = 0.04) (1.6 [1.0; 3.0], 1.3 [0.6; 1,6] and 3.7 [2.8; 5.3] % blood volume, respectively).High doses of FM preparation (2.5 and 5.0 mg/kg) minimized blood loss due to activation of coagulation and thrombus formation, which was illustrated by a 7.0–8.0-fold increase in D-dimer level (compared to placebo). 0.25 mg/kg of FM preparation did not lead to an increase of D-dimer content, although the blood loss was greatly reduced. Conclusion. The data obtained show the presence of unique hemostatic properties in low-dose FM preparation (0.25 mg/kg), which allows creating system hemostatic agents of a new generation.

Key words

hemostatic system, fibrin monomer, liver injury, parenchymal hemorrhage, hemostatic effect, rabbits

References

A guideline to experimental (preclinical) study of new pharmacological agents / Ed. R.Yu. Khabriev. Moscow: Meditsina, 2005. 832 p. [In Russian]

A guideline to preclinical drug studies. Part one / Ed. А.N. Mironov. М.: Grif i К, 2012. 944 p. [In Russian].

Belitser V.A., Varetskaya T.V. Fibrinogen and fibrin: molecular structure, self-assembly of fibers. Uspekhi sovremennoy biologii = Biology Bulletin Reviews. 1975. 80. (1). 5–21. [In Russian].

Damage Control Resuscitation at Level IIb/III Treatment Facilities / Joint Theater Trauma System Clinical Practice Guideline. Feb. 2013. 32 р.

Dreijer A.R., Kruip M.J., Diepstraten J., Polinder S., Brouwer R., Leebeek F.W., Vulto A.G., Bemt P.M. Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol // BMJ Open. 2016. 6. (12). e011537.

European convention for the protection of vertebrate animals used for experimental and other scientific purposes. Strasburg: Council of Europe, 1986. 11 р.

Kudryashov B.А., Molchanova L.V., Kalishevskaya T.M., Bazaz'yan G.G., Pastorova V.E., Sytina N.P. About the functional state of anticoagulant system in the setting of fibrin monomer intravenous administration // Problems of medical chemistry. 1969. XV. (5). 483-486. [In Russian].

Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature. 1970. 227. (5259). 680-685.

Levi M. Management of bleeding in patients treated with direct oral anticoagulants // Crit. Care. 2016. 20. 249.

Lugovskoj EH.V., Makogonenko E.M., Komisarenko S.V. Molecular mechanisms of fibrin formation and degradation: physicochemical and immunochemical analysis. Kiev: Naukova dumka, 2013. 230 p. [In Russian].

Makarov V.А., Belozerskaya G.G., Momot А.P., Sokolov EH.А., Ter-Аrutyunyants А.А., Vasil'eva T.M. Hemostatic agent. Patent RF No. 2308287; published 20.10.2007. [In Russian].

Momot А.P., SHakhmatov I.I., Lomaev I.S., Terekhov S.S. The method of fibrin monomer commercial production from blood plasma. Patent RF No. 2522237; published 15.05.2014. [In Russian].

Putnam F.W. The Plasma Proteins. 2nd ed. Vol. 2. N.Y.: Acad. Press, 1975. 148 p.

Reference Book. Physiological, biochemical and biometric indicators of normal values for experimental animals / Ed. V.G. Makarov. Saint-Petersburg: LEMA, 2013. 116 p. [In Russian].

Rossaint R., Bouillon B., Cerny V., Coats T.J., Duranteau J., Fernández-Mondéjar E., Filipescu D., Hunt B.J., Komadina R., Nardi G., Neugebauer E.A., Ozier Y., Riddez L., Schultz A., Vincent J.L., Spahn D.R. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition // Crit. Care. 2016.12. (20). 100.

Soe G.L., Kohno I., Inuzuka K., Itoh Y., Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma // Blood. 1996. 188. (6). 2109-2117.

Zubairov D.M. Molecular basis of blood clotting and thrombogenesis. Kazan': Fen, 2000. 367 p. [In Russian].

About Authors (Correspondence):

Vdovin V.M. – candidate of medical sciences, associate professor, head of the department of pathological physiology, e-mail: erytrab@gmail.com

Full Text

snmzh_1-2019_momot_6-12.pdf

Received: 27/02/2019

Accepted: 27/02/2019